Topline results were announced from two phase 3 trials evaluating doravirine/islatravir (DOR/ISL) in adults with virologically ... care antiretroviral therapy (ART) through week 48.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback